Y.S.P. Industries


Y.S.P. Industries
Concise Prescribing Info
Bacterial infections caused by susceptible strains: Acute sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, mild to moderately severe pelvic inflammatory disease. Complicated skin & skin structure infections, intra-abdominal infections including polymicrobial infections eg, abscesses.
Dosage/Direction for Use
Adult >18 yr 400 mg once daily. Duration of treatment: Acute exacerbation of chronic bronchitis 5 days. Community-acquired pneumonia 10 days. Acute sinusitis 7 days. Mild to moderately severe pelvic inflammatory disease 14 days. Complicated skin & skin structure infection 7-21 days. Complicated intra-abdominal infection 5-14 days.
May be taken with or without food: Swallow whole w/ sufficient liqd/water.
Hypersensitivity to moxifloxacin or other quinolones. History of quinolone-related tendon disease/disorder. Congenital or documented acquired QT prolongation, electrolyte disturbances particularly in uncorrected hypokalaemia, bradycardia, heart failure w/ reduced left ventricular ejection fraction, previous history of symptomatic arrhythmias. Not to be used concurrently w/ other QT interval-prolonging drugs. Hepatic impairment (Child-Pugh C), increased transaminases >5-fold ULN. Pregnancy & lactation. Patients <18 yr.
Special Precautions
Discontinue use if severe hypersensitivity, signs & symptoms suggestive of severe cutaneous ARs, antibiotic-associated diarrhoea & colitis or 1st sign of tendinitis occur. Not recommended in patients w/ complicated pelvic inflammatory disease; MRSA infections. Avoid use in patients w/ known history of serious ARs w/ quinolone- or fluoroquinolone-containing products; myasthenia gravis. Increased risk of aortic aneursym & dissection. Patients w/ ongoing proarrhythmic conditions eg, acute myocardial ischaemia or QT prolongation; bullous skin reactions eg, SJS, TEN; CNS disorders, risk factors predisposing to seizures or lowering seizure threshold; sensory or sensorimotor polyneuropathy; psychosis or history of psychiatric disease; solid organ transplants; vision disorders; G6PD deficiency. Monitor blood glucose in diabetic patients. Maintain adequate fluid intake. Avoid exposure to UV irradiation, extensive or strong sunlight. Interference w/ Mycobacterium spp culture test. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Avoid concomitant use w/ corticosteroids. Concomitant use w/ medications reducing K levels. May affect ability to drive or use machines. Severe hepatic disorders. Renal impairment. Not to be used during pregnancy. Childn & adolescents <6 yr. Elderly >60 yr.
Adverse Reactions
Superinfections; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pains; increased transaminases.
Drug Interactions
Increased risk of ventricular arrhythmias including Torsade de pointes w/ class IA & III antiarrhythmics, antipsychotics, TCAs, certain antimicrobials & antihistamines, cisapride, vincamine IV, bepridil, diphemanil. Reduced systemic availability w/ charcoal. Increased oral anticoagulant activity. Caution w/ loop- & thiazide-type diuretics, high-dose laxatives & enemas, corticosteroids, amphotericin B, Mg- & Al-containing antacids, Fe- or Zn-containing agents, didanosine, sucralfate.
MIMS Class
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Moxifcin FC tab 400 mg
1 × 5's;10 × 10's;10 × 5's;2 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in